Third Harmonic Bio reports THB335 program next steps
The Company intends to continue THB335 development activities through the first half of 2025 to prepare for the initiation of a 12-week, ...
Third Harmonic Bio Announces Fourth Quarter and Full Year 2024 Financial Results
Recently presented THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Strategic alternatives process underway to maximize value creation across ...
Third Harmonic Bio downgraded to Hold from Buy at Stifel
Stifel downgraded Third Harmonic Bio (THRD) to Hold from Buy with a price target of $5, down from $23, following the company’s decision to ...
Mena FN3d
Third Harmonic Bio Announces Fourth Quarter And Full Year 2024 Financial Results
THB335 Program Next Steps The Company intends to continue THB335 development activities through the first half of 2025 to prepare for the initiation of a 12-week, placebo-controlled Phase 2 study ...